Trial
NCT05191797
Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Washington
Collaborators
National Cancer Institute (NCI); Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Condition
Extensive Stage Lung Small Cell Carcinoma
Intervention
Bomedemstat
Why stopped
Closed per SRC Low Accrual Policy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-26